BioNTech SE research snapshot
BNTX AI stock analysis currently reads BioNTech SE as a well-capitalized oncology and immunotherapy developer transitioning away from COVID-19 vaccine dependence. At the July 11, 2026 data cutoff, BNTX last closed near $92.98 on July 9, with an implied market capitalization of about $23.51 billion. The key attraction is a large cash and securities balance funding late-stage oncology programs; the key risks are continuing losses, lower COVID revenue, clinical outcomes, and a planned co-founder leadership transition. This is informational research, not investment advice.
Current price
$92.98
Market cap
$23.51 billion
AI score
61 / 100
Rating
Cash-backed oncology transition with high clinical and leadership risk
Trend status
Range-bound below the 200-day moving average
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BioNTech sells COVID-19 vaccines and builds oncology medicines, immunomodulators, and antibody-drug conjugates that must prove clinical benefit and commercial adoption. | Medium |
| Moat | mRNA expertise, oncology research, manufacturing, regulatory experience, intellectual property, and partnerships create barriers, but large pharma and other biotech firms compete for the same targets. | Medium |
| Management | The founders built the mRNA platform and COVID franchise, but their planned transition by the end of 2026 makes successor quality and capital-allocation discipline central risks. | Medium |
| Financial trend | FY2025 revenue was €2.870 billion and net loss was €1.136 billion. Q1 2026 revenue was €118.1 million and net loss was €531.9 million, reflecting seasonal COVID demand and oncology investment. | High |
| Valuation | At $92.98, BNTX traded near 1.09x book value and 32.51x trailing free cash flow, while P/E is not meaningful because trailing EPS is negative. | Medium |
| Technical trend | The July 9 snapshot placed price near the 50-day moving average but below the 200-day moving average, which supports a neutral to cautious technical view. | Medium |
| Risk level | Risk is high because late-stage oncology studies, spending, COVID demand, competition, regulatory decisions, integration, and executive succession can all move the equity sharply. | High |
| AI confidence | Reported facts are well supported, but any forecast has limited confidence because clinical evidence and strategic decisions can outweigh historical financial trends. | Medium |
| Investment certainty | Cash runway does not equal a proven earnings stream. Investment certainty remains below data confidence until oncology programs produce repeatable commercial evidence. | Low-medium |
BNTX AI stock forecast
The BNTX AI stock forecast uses scenario ranges rather than a precise price prediction. The required three-scenario EPS and P/E calculation produced negative values because trailing EPS is negative, so it is not suitable as a price target. The practical range instead reflects cash coverage, oncology data, COVID revenue, cost execution, and the market value assigned to the pipeline.
$120 to $145
More likely if pumitamig, gotistobart, antibody-drug conjugate, or mRNA oncology data are convincing, the BMS collaboration advances, costs remain controlled, and investors value the net cash plus a credible multi-product oncology franchise.
$85 to $110
More likely if 2026 revenue follows the €2.0 billion to €2.3 billion guide, the cash balance remains strong, data are mixed but adequate, and the market waits for clearer approval and launch evidence.
$60 to $75
More likely if pivotal studies disappoint, COVID revenue falls faster than expected, spending or integration costs exceed plans, leadership transition creates execution concerns, or the market discounts the pipeline more heavily.
BNTX AI technical analysis
BNTX AI technical analysis is neutral to cautious as of the July 11, 2026 cutoff. StockAnalysis showed a July 9 close of $92.98, a 50-day moving average of $92.43, a 200-day moving average of $99.03, and RSI of 51.65. Price was near its 50-day average but below its 200-day average, so a durable uptrend still needs confirmation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $92.98 | July 9, 2026 closing quote used for market-cap math and technical context. |
| Near support | $92 to $93 | The 50-day moving average near $92.43 is the nearest trend reference. |
| Secondary support | $79 to $80 | The 52-week low area near $79.52 is the next visible support zone from the chart snapshot. |
| Resistance | $99 to $100 | The 200-day moving average near $99.03 is the first meaningful recovery hurdle. |
| Higher resistance | $124 | The chart snapshot listed a 52-week high of $124.00, a larger upside reference if price reclaims the long-term average. |
| Momentum | RSI 51.65, neutral | Momentum was neither oversold nor overbought, so clinical news and volume confirmation matter more than RSI alone. |
| Volume | About 1.00 million 20-day average shares | A breakout should be judged against average volume because oncology and earnings news can create short-lived spikes. |
| Volatility | Elevated event-driven biotech volatility | Clinical readouts, regulatory updates, earnings, spending decisions, and executive news can override chart levels. |
| Invalidation | Close below $92, then $79.52 | A sustained break below the 50-day average weakens the range setup. A break below the 52-week-low area would require a full thesis review. |
BNTX AI trading strategy
The BNTX AI trading strategy is a rules-based research framework for an event-driven biotechnology stock. It is not personal advice and should be used with live prices, position sizing, filings, trial calendars, and independent risk limits.
Watch for BNTX to hold the $92 to $93 support area and reclaim the 200-day moving average near $99 with above-average volume and no adverse clinical or management news.
A sustained close below the 50-day average should reduce confidence. A break below $79.52 should invalidate the range thesis and prompt a fresh fundamental review.
If BNTX revisits support without new adverse data, compare the price move with cash preservation, 2026 revenue guidance, trial milestones, and the probability of oncology commercialization.
Do not treat a clinical or leadership-driven selloff as ordinary technical noise. Define a loss limit before entry because news gaps can be large.
Track quarterly revenue, cash and securities, R&D and SG&A guidance, BMS collaboration progress, pumitamig and gotistobart studies, ADC milestones, COVID demand, buyback execution, and management succession.
Reduce confidence if cash declines without stronger clinical or commercial evidence, if cost savings do not materialize, or if pivotal timelines repeatedly slip.
Investment research summary
BioNTech converts mRNA, immuno-oncology, antibody-drug conjugate, clinical-development, and manufacturing capabilities into medicines that need measurable patient benefit, regulatory approval, reimbursement, and reliable delivery.
The moat is a combination of mRNA expertise, cancer research, intellectual property, manufacturing, regulatory know-how, data, and partnerships. It is not permanent: better clinical profiles, faster execution, or stronger commercial infrastructure from competitors can narrow it.
The thesis fails if oncology data do not translate into approvals, the acquired and partnered programs do not justify their cost, COVID revenue erodes faster than spending, leadership transition disrupts execution, or the cash balance is spent before a durable product base arrives.
Management built a globally important mRNA company and has focused capital on oncology, but the planned departure of co-founders Ugur Sahin and Özlem Türeci by the end of 2026 creates key-person and succession risk. The next team must allocate capital carefully and execute launches.
Cancer immunotherapy and precision medicines remain long-term growth areas. BioNTech sits in a competitive field where large trials, combination science, safety, reimbursement, and sales execution determine whether a promising platform becomes a durable commercial business.
The balance sheet provides a meaningful cushion, but it is not a complete margin of safety because the market must fund years of development before commercial success is proven. Negative EPS makes a normal P/E valuation unreliable; the key question is the value created per unit of cash consumed.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BNTX price | $92.98 at the July 9, 2026 close | StockAnalysis quote snapshot | July 11, 2026 |
| Market capitalization | $23.51 billion, verified as $92.98 x 252.884261 million shares | financial_rigor.py, BioNTech Q1 2026 release, and StockAnalysis | July 11, 2026 |
| FY2025 revenue | €2.870 billion | BioNTech FY2025 results and Annual Report cross-check | July 11, 2026 |
| FY2025 net loss | €1.136 billion | BioNTech FY2025 results and Annual Report cross-check | July 11, 2026 |
| Q1 2026 revenue and net loss | €118.1 million revenue and €531.9 million net loss | BioNTech Q1 2026 financial results | July 11, 2026 |
| Cash, cash equivalents, and security investments | €16.763 billion at March 31, 2026 | BioNTech Q1 2026 financial results | July 11, 2026 |
| 2026 revenue guidance | €2.0 billion to €2.3 billion | BioNTech Q1 2026 financial results | July 11, 2026 |
| Valuation math | P/E not meaningful with negative EPS; P/B about 1.09x and P/FCF about 32.51x | financial_rigor.py using StockAnalysis per-share inputs | July 11, 2026 |
| Moving averages and momentum | 50-day $92.43, 200-day $99.03, RSI 51.65 | StockAnalysis technical snapshot | July 11, 2026 |
This BNTX AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on public filings, quote snapshots, technical data, and third-party sources available as of July 11, 2026. They may be wrong, incomplete, or outdated after earnings, trial data, regulatory decisions, leadership changes, cash-burn updates, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
